NCT05849389View on ClinicalTrials.gov

Vosoritide for Short Stature in Turner Syndrome

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 12, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Turner SyndromeShort Stature
Interventions
DRUG

Vosoritide

Vosoritide administered daily via subcutaneous injection for 12 months using the FDA approved weight-based dosing band strategy for achondroplasia.

Trial Locations (1)

20010

RECRUITING

Children's National Hospital, Washington D.C.

All Listed Sponsors
lead

Roopa Kanakatti Shankar, MBBS, MS

OTHER